[1] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B:A 2015 update[J]. J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1941-1960.
|
[2] Chinese Society of Infectious Disease,Chinese Society of Hepatology,Chinese Medical Association. The expert consensus on functional cure of chronic hepatitis B[J]. J Clin Hepatol,2019,35(8):1693-1701.(in Chinese)中华医学会感染病学分会,中华医学会肝病学分会.慢性乙型肝炎临床治愈(功能性治愈)专家共识[J].临床肝胆病杂志,2019,35(8):1693-1701.
|
[3] YANG S,LI Y,QUAN M,et al. Response prediction in chronic hepatitis B patients with HBe Ag positive treated with 24weeks pegylated interferon therapy[J]. Chin J Liver Dis(Electronic Edition),2018,10(1):28-32.(in Chinese)杨松,李玥,全敏,等.聚乙二醇化干扰素治疗HBe Ag阳性慢性乙型肝炎患者24周的应答预测[J].中国肝脏病杂志(电子版),2018,10(1):28-32.
|
[4] CHEN JL,YUAN ZH. Influence of interferon and nucleos(t)ide analogues on HBV cccDNA and functional cure of chronic hepatitis B[J]. J Clin Hepatol,2019,35(6):1181-1187.(in Chinese)陈捷亮,袁正宏.干扰素和核苷(酸)类似物治疗对HBV cccDNA的影响与慢性乙型肝炎的功能性治愈[J].临床肝胆病杂志,2019,35(6):1181-1187.
|
[5] Chinese Society of Infectious Diseases,Chinese Medical Association; Chinese Society of Hepatology,Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2019)[J]. J Clin Hepatol,2019,35(12):2648-2669.(in Chinese)中华医学会感染病学分会,中华医学会肝病学分会.慢性乙型肝炎防治指南(2019年版)[J].临床肝胆病杂志,2019,35(12):2648-2669.
|